Tempest Therapeutics, Inc.
TPSTNasdaq
$0.97
↓ -1.0%Jul 17 close · end-of-day
Price
1Y↓ -85.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$10.6M
Enterprise Value
$8.8M
P/E
—
P/S
—
P/B
12.8
EV/EBITDA
—
PEG
—
FCF Yield
-249.8%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$43.1M
Free Cash Flow (TTM)
-$26.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-5243.1%
ROIC
—
Debt / Equity
—
Net Cash
$1.8M
Return 1Y
-85.5%
Company profile
Tempest Therapeutics Inc. engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors.
- CEO
- Stephen R. Brady
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- California
- Website
- tempesttx.com
Earnings
TPST Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$2.53↓ -19.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$19.3M | -$27.0M | -$34.6M | -$29.2M | -$42.0M | -$26.6M |
| Net income | -$19.2M | -$28.3M | -$35.7M | -$29.5M | -$41.8M | -$26.3M |
| Diluted EPS | -$41.03 | -$7.47 | -$3.09 | -$1.91 | -$19.50 | -$6.33 |
| Operating cash flow | -$19.0M | -$26.0M | -$31.1M | -$27.4M | -$33.0M | -$26.8M |
| Free cash flow | -$19.1M | -$26.1M | -$31.6M | -$27.5M | -$33.5M | -$26.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.6M | -$10.6M | -$13.9M | -$10.9M | -$8.0M | -$3.6M | -$4.1M | -$27.7M |
| Net income | -$9.6M | -$10.6M | -$13.8M | -$10.9M | -$7.9M | -$3.5M | -$4.0M | -$27.7M |
| Diluted EPS | -$5.52 | -$5.32 | -$4.04 | -$3.16 | -$2.07 | -$0.79 | -$0.31 | -$2.53 |
| Operating cash flow | -$5.5M | -$10.2M | -$10.1M | -$8.0M | -$8.4M | -$6.8M | -$3.6M | -$7.6M |
| Free cash flow | -$5.8M | -$10.2M | -$10.2M | -$8.0M | -$8.4M | -$6.8M | -$3.6M | -$7.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-24 | Angel Matthew· CEO and President | Buy | 231,482 | $2.16 | $500,001.12 | filing |
| 2026-03-24 | Angel Matthew· CEO and President | Buy | 231,482 | $2.16 | $500,001.12 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.